Coronavirus disease 2019 vaccines:landscape of global studies and potential risks  

作　　者：Hu-Da-Chuan Jiang Yan-Yang Tao Si-Yue Jia Jing-Xin Li Feng-Cai Zhu 

机构地区：[1]School of Public Health,Southeast University,Nanjing,Jiangsu 210009,China [2]NHC Key Laboratory of Enteric Pathogenic Microbiology,Jiangsu Provincial Center for Disease Control and Prevention,Nanjing,Jiangsu 210009,China [3]Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 210009,China

出　　处：《Chinese Medical Journal》2021年第17期2037-2044,共8页中华医学杂志（英文版）

摘　　要：With the outbreak of the coronavirus disease 2019(COVID-19)pandemic,the importance of vaccines in epidemic prevention and public health has become even more obvious than ever.However,the emergence of multiple severe acute respiratory syndrome coronavirus 2 variants worldwide has raised concerns about the effectiveness of current COVID-19 vaccines.Here,we review the characteristics of COVID-19 vaccine candidates in five platforms and the latest clinical trial results of them.In addition,we further discuss future directions for the research and development of the next generation of COVID-19 vaccines.We also summarize the serious adverse events reported recently after the large-scale vaccination with the current COVID-19 vaccines,including the thromboembolism caused by the AstraZeneca and Johnson&Johnson vaccines.

关 键 词：Severe acute respiratory syndrome coronavirus 2 COVID-19 VACCINE IMMUNOGENICITY SAFETY Clinical trial 

分 类 号：R392-33[医药卫生—免疫学]